Drug Profile
Anti-lymphotoxin beta receptor antibody
Latest Information Update: 01 Mar 2007
Price :
$50
*
At a glance
- Originator Biogen Idec
- Class Antibodies
- Mechanism of Action Lymphotoxin beta receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 21 Feb 2007 Discontinued - Preclinical for Cancer in USA (Parenteral)
- 07 Aug 2006 Preclinical trials in Cancer in USA (Parenteral)
- 19 May 2003 No development reported - Preclinical for Cancer in USA (Parenteral)